Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 May;192(5):1404-6.
doi: 10.1016/j.ajog.2004.12.033.

Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study

Jennifer Hamm  1 , Zoi Russell, Tracey Botha, S J Carlan, Kris Richichi
Affiliations
Clinical Trial

Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study

Jennifer Hamm et al. Am J Obstet Gynecol. 2005 May.

Abstract

Objective: The purpose of this study was to assess the efficacy of buccal misoprostol to decrease uterine atony, hemorrhage, and the need for additional uterotonic agents during cesarean delivery.

Study design: Patients who underwent cesarean delivery were assigned randomly to either 200-microg misoprostol or placebo placed in the buccal space. A dilute intravenous oxytocin infusion was given to all patients at delivery of the placenta. The primary outcome variable was the need for additional uterotonic agents.

Results: A total of 352 women received random assignments. Demographic and intrapartum characteristics were similar between the groups. More women in the placebo group required 1 additional uterotonic agent (43% vs 26%; P < .01; relative risk, 1.3; 95% CI, 1.10, 1.50). There was not a difference between the groups in the incidence of postpartum hemorrhage or a difference in preoperative and postoperative hemoglobin level.

Conclusion: Buccal misoprostol reduces the need for additional uterotonic agents during cesarean delivery.

PubMed Disclaimer

Publication types